We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AKRBP:EURONEXT OSLOAker BP ASA Analysis

Data as of 2026-05-29 - not real-time

NOK 332.60

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Aker BP is trading at NOK 332.6, comfortably above its 20‑day SMA of ~347.7 and 50‑day SMA of ~345.1, yet still below the longer‑term 200‑day SMA of ~282.1, indicating a short‑term bullish tilt within a broader uptrend. The RSI sits at 43, suggesting neutral momentum, while the MACD histogram is negative and the signal line is bearish, warning of potential near‑term downside. The company posted Q1 profit in line with expectations and highlighted a 97% production efficiency, with key offshore projects slated to start output in 2027, reinforcing its operational credibility. However, fundamentals reveal a PE of ~39.5 versus an industry average of ~20.5, a payout ratio of ~280% and negative free cash flow, raising serious concerns about dividend sustainability. Debt remains high at a debt‑to‑equity of ~84.6% and free cash flow is negative, while the DCF‑derived fair value of ~88.1 NOK implies the stock is markedly overvalued, with a downside of roughly 4% from current levels. The dividend yield of 7.5% appears attractive but is unlikely to be maintained given cash flow constraints. Volatility is elevated at over 40% on a 30‑day basis and beta is slightly negative, reflecting a defensive price reaction to broader market moves. Overall, while the operational outlook is solid, the valuation and capital structure pressures suggest caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and neutral RSI signal limited upside
  • Current price exceeds DCF fair value, indicating overvaluation
  • Dividend payout ratio unsustainably high

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Projects expected to generate output in 2027
  • Forward PE of ~12.9 suggests earnings growth potential
  • High debt and negative free cash flow remain balance‑sheet concerns

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Persistent overvaluation relative to intrinsic value
  • Elevated sector cyclicality and regulatory headwinds
  • Unsustainable dividend policy and deteriorating cash generation

Key Metrics & Analysis

Financial Health

Revenue Growth-4.70%
Profit Margin5.31%
P/E Ratio39.5
ROE4.75%
ROA9.21%
Debt/Equity84.63
P/B Ratio2.0
Op. Cash FlowNOK6.9B
Free Cash FlowNOK-2700312576
Industry P/E20.5

Technical Analysis

TrendBullish
RSI43.4
SupportNOK 320.30
ResistanceNOK 373.80
MA 20NOK 347.66
MA 50NOK 345.05
MA 200NOK 282.15
MACDBearish
VolumeDecreasing
Fear & Greed Index93.66

Valuation

Fair ValueNOK 88.13
Target PriceNOK 320.11
Upside/Downside-3.75%
GradeOvervalued
TypeBlend
Dividend Yield7.49%

Risk Assessment

Beta-0.32
Volatility41.43%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.